高尿酸血症与血管内皮损伤的基础与临床研究
|
摘要
背景：尿酸是嘌呤代谢产物,人类进化过程中尿酸酶基因突变,导致功能失活,使人的血尿酸水平较其它哺乳动物高。临床观察到高尿酸血症与心血管疾病有密切联系。流行病研究发现,人群中随血尿酸水平升高,心血管疾病和代谢综合征等的发病率随之升高。多项研究显示血管内皮功能损伤是心血管疾病的重要始动因素,而关于尿酸影响血管内皮损伤的基础研究较少,尚存在一定分歧。
目的：1)通过人群研究进一步证实高尿酸血症与其他代谢性疾病和心血管疾病的相关性,并探索单纯无症状性高尿酸血症人体内是否存在血管内皮功能损伤；2)利用尿酸酶抑制剂氧嗪酸钾升高大鼠血清尿酸水平,建立动物模型,并在动物模型观察单纯高尿酸对血管内皮功能的影响；3)通过建立长期高尿酸血症模型,观察单纯高尿酸血症能否造成大鼠主动脉及肾脏的病理变化。
方法：1)多因素分析法分析2008年某体检人群病史、查体资料和生化检测指标,探讨高尿酸血症和各代谢异常的相关性；并选取单纯无症状性高尿酸血症94人,研究单纯无症状性高尿酸血症与血管内皮功能损伤的关系。2)使用2%的氧嗪酸饲料和1OOumol/L的尿酸水建立高尿酸血症动物模型,并使用别嘌醇阻止尿酸的升高,以NO、ET-1、ICAM作为血管内皮损伤的血清学指标,观察单纯升高尿酸对血管内皮损伤的影响。3)通过先使用2%的氧嗪酸饲料和1OOumol/L的尿酸水,后增加氧嗪酸灌胃的方法建立长期高尿酸血症动物模型,使用HE染色下内膜-中膜厚度、内皮炎性细胞浸润以及脂纹、脂斑的形成作为血管损伤的早期指标及肾叶间小动脉增殖、小动脉管壁增厚作为肾脏损伤的指标,分析高尿酸血症对大鼠主动脉及肾脏的病理变化,并通过对主动脉和肾脏的eNOS、ET-1、ICAM等的免疫组化染色和血清NO、ET-1、ICAM的检测进一步寻找血管损伤的证据。
结果：1)人群高尿酸血症患病率14.3%,男性21.4%,女性11.5%；高尿酸血症组各代谢异常的患病率均较非高尿酸血症组高(P<0.01),在调整了年龄性别后差异仍有统计学意义；高尿酸血症增加各代谢异常的发生危险,多元Logistic回归分析后发现血清尿酸水平和肥胖、高血压、低HDL-C、高TG、脂肪肝显著独立相关。高尿酸血症组hs-CRP血清浓度较非高尿酸血症组明显高,差异有显著性(P<0.01)；但两组TNF-α浓度差异无显著性；高尿酸血症组血清NO浓度较非高尿酸血症人群明显降低(P<0.01),血清ET-1水平及ICAM水平均较非高尿酸血症人群明显升高(P<0.01)2)造模17天时单造模组ET-1、ICAM浓度较对照组升高,但无显著性差异,分别较单治疗组和造模+治疗组升高,提示高尿酸血症能够升高ET-1、ICAM,且降尿酸治疗,可以降低ET-1、ICAM:造模17天时单造模组NO浓度较对照组显著降低(P<0.05),分别较单治疗组和造模+治疗组降低,提示高尿酸血症能够降低NO浓度,且降尿酸治疗,可以使NO浓度恢复。3)模型组部分大鼠可见动脉壁内皮细胞内膜-中膜厚度轻度增加,但无显著性差异(P=0.067)；浸润于内膜的炎性细胞数轻度增多,差异无显著性(P=0.12)；模型组1只动物动脉内膜出现小脂斑,表现为大量泡沫细胞聚集成堆,周边可找到单核巨噬细胞。但病灶内未找到变性的胶原纤维。模型组主动脉内膜eNOS表达较对照组明显减少、ET-1、ICAM表达显著高于对照组(p<0.05),模型组肾脏小动脉增殖和小动脉管壁厚度较对照组明显增加；模型组ET-1、ICAM表达显著高于对照组,但eNOS表达两组间无显著性差异。
结论：1)高尿酸血症与肥胖、高血压、高血糖、血脂紊乱、脂肪肝等多项代谢异常均有显著相关性,是其独立危险因素。单纯无症状高尿酸血症患者存在血管内皮功能损伤,高尿酸血症可能通过损伤血管内皮功能和刺激C反应蛋白的产生而参与高血压、血脂异常、糖尿病、冠心病等疾病的发生发展。2)短期高尿酸血症(2周)可以降低大鼠血清NO值,轻度升高ET-1和ICAM值。3)长期高尿酸血症(12周)可以造成S-D大鼠主动脉早期内皮损伤,但不能形成典型动脉粥样硬化,可以引起叶间小动脉增殖及小动脉管壁增厚,但短期内并未影响肾脏功能。
Background. Uric acid is the product of purine metabolism; however, a relatively higher level of serum uric acid in human is observed than that in other mammals since genetic mutations. Hyperuricemia often comes with cardiovascular diseases. The incidences of cardiovascular disease are related to the elevation of serum uric acid in general population. The role of Endothelial dysfunction in cardiovascular diseases has been certified by many research. However, there are few reports on the effect of uric acid on endothelial dysfunction and some are contradictory.
Objective.1) To invesgate the relationship of hyperuricemia and other metobolitic disorders in a group during the annual health examination and the role hyperuricemia in endothelial dysfunction.2) To study the the role hyperuricemia in endothelial dysfunction, in a hyperuricemia animal model made by feed with Oxonic Acid contaminated forage; 3) To identify if hyperuricemia can induce arota and kidney pathology through copy a continuous long-term hyperuricemia animal model.
Methods.1) Multiple variance analyis of the association of hyperuricemia and other metabolitic disorder; Chose 94 pure asymptom hyperuricemia people as patient and 94 people with same age and gender as control to determine the role of hyperuricemia in endothelial dysfunction.2) Use 2%OA forage and 1OOumol/L uric acid to copy a hyperuricemia and use allopurinol as a blocker, chose NO, ET-1, ICAM as marks of endothelial dysfunction, to identify the mechanism of uric acid in endothelial dysfunction,,3) Use 2%OA forage and 1OOumol/L uric acid plus OA lavage to copy a continuous long-term hyperuricemia animal model, and eNOS, ET-1、ICAM expression in arota and kidney to find out the role of uric acid in cardiovascular diseases。
Results.1) 14.5%people have hyperuricemia in the health examination. The hyperuricemia group has a high rate of ther metabolism dysfunction. Concentrate of serum uric acid has a strong association with age, gender, BMI.SysBp, DiaBp, HDL-C、LDL-C、TC、TG、nonHDL-C, Glu Cr、ALT、AIP、fatty liver by analyzing in bivariate correlation。Concentrate of serum uric acid was independently associated with obesity, hypertension, low HDL-C, hypertriglyceridemia, and fatty liver by analyzing in logistic multiple regression. The hs-CRP concentration is higher in the aymptom hyperuricemia, but no difference in TNF-αlevel between these two groups. The NO concentration is lower in the asymptom hyperuricemia group, whereas the ET-1 and ICAM level is higher in the aymptom hyperuricemia.2) Hyperuricemia rat has higer ET-1、ICAM level and lower NO concentration; Allopurinol can block the change at D17.3). Hyperuricemia rat has tiny damage whereas rats in control group is totally normal; Hyperuricemia rat has less eNOS expression, moreET-、ICAM expression in arota(p<0.05); Hyperuricemia rat has higher ET-1、ICAM expression than the control group while the same eNOS expression in kidney.
Conclusion.1) Hyperuricemia was significantly associated with obesity, hypertension, low HDL-C, hypertriglyceridemia, and fatty liver, independently in the health examination group. Asymptom hyperuricemia can induce endothelial dysfunction.2) Short-term hyperuricemia has decrease the production of NO concentration in rat.3) Long-term hyperuricemia can induce mild pathology in rat arota and kidney.
目的：1)通过人群研究进一步证实高尿酸血症与其他代谢性疾病和心血管疾病的相关性,并探索单纯无症状性高尿酸血症人体内是否存在血管内皮功能损伤；2)利用尿酸酶抑制剂氧嗪酸钾升高大鼠血清尿酸水平,建立动物模型,并在动物模型观察单纯高尿酸对血管内皮功能的影响；3)通过建立长期高尿酸血症模型,观察单纯高尿酸血症能否造成大鼠主动脉及肾脏的病理变化。
方法：1)多因素分析法分析2008年某体检人群病史、查体资料和生化检测指标,探讨高尿酸血症和各代谢异常的相关性；并选取单纯无症状性高尿酸血症94人,研究单纯无症状性高尿酸血症与血管内皮功能损伤的关系。2)使用2%的氧嗪酸饲料和1OOumol/L的尿酸水建立高尿酸血症动物模型,并使用别嘌醇阻止尿酸的升高,以NO、ET-1、ICAM作为血管内皮损伤的血清学指标,观察单纯升高尿酸对血管内皮损伤的影响。3)通过先使用2%的氧嗪酸饲料和1OOumol/L的尿酸水,后增加氧嗪酸灌胃的方法建立长期高尿酸血症动物模型,使用HE染色下内膜-中膜厚度、内皮炎性细胞浸润以及脂纹、脂斑的形成作为血管损伤的早期指标及肾叶间小动脉增殖、小动脉管壁增厚作为肾脏损伤的指标,分析高尿酸血症对大鼠主动脉及肾脏的病理变化,并通过对主动脉和肾脏的eNOS、ET-1、ICAM等的免疫组化染色和血清NO、ET-1、ICAM的检测进一步寻找血管损伤的证据。
结果：1)人群高尿酸血症患病率14.3%,男性21.4%,女性11.5%；高尿酸血症组各代谢异常的患病率均较非高尿酸血症组高(P<0.01),在调整了年龄性别后差异仍有统计学意义；高尿酸血症增加各代谢异常的发生危险,多元Logistic回归分析后发现血清尿酸水平和肥胖、高血压、低HDL-C、高TG、脂肪肝显著独立相关。高尿酸血症组hs-CRP血清浓度较非高尿酸血症组明显高,差异有显著性(P<0.01)；但两组TNF-α浓度差异无显著性；高尿酸血症组血清NO浓度较非高尿酸血症人群明显降低(P<0.01),血清ET-1水平及ICAM水平均较非高尿酸血症人群明显升高(P<0.01)2)造模17天时单造模组ET-1、ICAM浓度较对照组升高,但无显著性差异,分别较单治疗组和造模+治疗组升高,提示高尿酸血症能够升高ET-1、ICAM,且降尿酸治疗,可以降低ET-1、ICAM:造模17天时单造模组NO浓度较对照组显著降低(P<0.05),分别较单治疗组和造模+治疗组降低,提示高尿酸血症能够降低NO浓度,且降尿酸治疗,可以使NO浓度恢复。3)模型组部分大鼠可见动脉壁内皮细胞内膜-中膜厚度轻度增加,但无显著性差异(P=0.067)；浸润于内膜的炎性细胞数轻度增多,差异无显著性(P=0.12)；模型组1只动物动脉内膜出现小脂斑,表现为大量泡沫细胞聚集成堆,周边可找到单核巨噬细胞。但病灶内未找到变性的胶原纤维。模型组主动脉内膜eNOS表达较对照组明显减少、ET-1、ICAM表达显著高于对照组(p<0.05),模型组肾脏小动脉增殖和小动脉管壁厚度较对照组明显增加；模型组ET-1、ICAM表达显著高于对照组,但eNOS表达两组间无显著性差异。
结论：1)高尿酸血症与肥胖、高血压、高血糖、血脂紊乱、脂肪肝等多项代谢异常均有显著相关性,是其独立危险因素。单纯无症状高尿酸血症患者存在血管内皮功能损伤,高尿酸血症可能通过损伤血管内皮功能和刺激C反应蛋白的产生而参与高血压、血脂异常、糖尿病、冠心病等疾病的发生发展。2)短期高尿酸血症(2周)可以降低大鼠血清NO值,轻度升高ET-1和ICAM值。3)长期高尿酸血症(12周)可以造成S-D大鼠主动脉早期内皮损伤,但不能形成典型动脉粥样硬化,可以引起叶间小动脉增殖及小动脉管壁增厚,但短期内并未影响肾脏功能。
Background. Uric acid is the product of purine metabolism; however, a relatively higher level of serum uric acid in human is observed than that in other mammals since genetic mutations. Hyperuricemia often comes with cardiovascular diseases. The incidences of cardiovascular disease are related to the elevation of serum uric acid in general population. The role of Endothelial dysfunction in cardiovascular diseases has been certified by many research. However, there are few reports on the effect of uric acid on endothelial dysfunction and some are contradictory.
Objective.1) To invesgate the relationship of hyperuricemia and other metobolitic disorders in a group during the annual health examination and the role hyperuricemia in endothelial dysfunction.2) To study the the role hyperuricemia in endothelial dysfunction, in a hyperuricemia animal model made by feed with Oxonic Acid contaminated forage; 3) To identify if hyperuricemia can induce arota and kidney pathology through copy a continuous long-term hyperuricemia animal model.
Methods.1) Multiple variance analyis of the association of hyperuricemia and other metabolitic disorder; Chose 94 pure asymptom hyperuricemia people as patient and 94 people with same age and gender as control to determine the role of hyperuricemia in endothelial dysfunction.2) Use 2%OA forage and 1OOumol/L uric acid to copy a hyperuricemia and use allopurinol as a blocker, chose NO, ET-1, ICAM as marks of endothelial dysfunction, to identify the mechanism of uric acid in endothelial dysfunction,,3) Use 2%OA forage and 1OOumol/L uric acid plus OA lavage to copy a continuous long-term hyperuricemia animal model, and eNOS, ET-1、ICAM expression in arota and kidney to find out the role of uric acid in cardiovascular diseases。
Results.1) 14.5%people have hyperuricemia in the health examination. The hyperuricemia group has a high rate of ther metabolism dysfunction. Concentrate of serum uric acid has a strong association with age, gender, BMI.SysBp, DiaBp, HDL-C、LDL-C、TC、TG、nonHDL-C, Glu Cr、ALT、AIP、fatty liver by analyzing in bivariate correlation。Concentrate of serum uric acid was independently associated with obesity, hypertension, low HDL-C, hypertriglyceridemia, and fatty liver by analyzing in logistic multiple regression. The hs-CRP concentration is higher in the aymptom hyperuricemia, but no difference in TNF-αlevel between these two groups. The NO concentration is lower in the asymptom hyperuricemia group, whereas the ET-1 and ICAM level is higher in the aymptom hyperuricemia.2) Hyperuricemia rat has higer ET-1、ICAM level and lower NO concentration; Allopurinol can block the change at D17.3). Hyperuricemia rat has tiny damage whereas rats in control group is totally normal; Hyperuricemia rat has less eNOS expression, moreET-、ICAM expression in arota(p<0.05); Hyperuricemia rat has higher ET-1、ICAM expression than the control group while the same eNOS expression in kidney.
Conclusion.1) Hyperuricemia was significantly associated with obesity, hypertension, low HDL-C, hypertriglyceridemia, and fatty liver, independently in the health examination group. Asymptom hyperuricemia can induce endothelial dysfunction.2) Short-term hyperuricemia has decrease the production of NO concentration in rat.3) Long-term hyperuricemia can induce mild pathology in rat arota and kidney.
引文
1. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson, RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension.2002.40(3):355-60
2. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease:recent developments, and where do they leave us? Am J Med 2005; 118:816-26.
3. Feig DI, Kang DH, Johnson RJ. Uric Acid and Cardiovascular Risk. N Engl J Med 2008:359:1811-21.
4. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001.38:1101-6.
5.张浩军,张冰,刘小青.小鼠高尿酸高脂血症复合模型初探.[J]北京中医药大学学报200124(6)：29-30
6. Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults[J]. Int J Clin Pract, 2005,59:1276-1282.
7. Kanabrocki EL, Third JL, Ryan MD, et al. Circadian relationship of serum uric acid and nitric oxide[J]. JAMA,2000,283:2240-2241.
8. Kato M, Hisatome I, TomikuraY, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol.2005,96:1576-1578.
9. Khosla UM, Zharikov S, Finch JL,et al. Hyperuricemia induces endothelial dysfunction[J]. Kidney Int,2005,67:1739-1742.
10.方圻,游凯,林其燧等,中国正常人血清尿酸调查及其与血脂的关系.中华内科杂志,1983,22：434-438.
11.杜蕙,陈顺乐,王元等.上海市黄浦区社区高尿酸血症与痛风流行病学调查.中华风湿病学杂志,1998,2：75-78.
12.姜宝法,张源潮,徐晓菲,等.山东沿海地区痛风和高尿酸血症的流行病学调查[J].中国公共卫生,1999,15(3)：205-206
13.邵继红,莫宝庆,喻荣彬,等.南京市社区人群高尿酸血症与痛风的流行病学调查[J].疾病控制杂志,2003,7(4)：305-308
14.方卫纲,黄晓明,王玉等,高尿酸血症在北京地区1997人中的患病情况及相关因素分析.中华医学杂志,2006,86：1764-1768.
15. LeoNiskanen, David E. Laaksonen, Jaana Lindstr, et al. Serum Uric Acid as a Harbinger of Metabolic Outcome in Subjects With Impaired Glucose Tolerance. Diabetes Care, 2006,29, (3),709-711
16. Chin-Hsiao Tseng. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney International,2005,68(3). 796-801.
17. Peter Hovind, Peter Rossing, Lise Tarnow, et al. Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes An Inception Cohort Study. Diabetes 2009,58(7):1668-1671.
18. Adriana G. Ioachimescu, Danielle M. Brennan, Brian M. Hoar, et al. Serum Uric Acid Is an Independent Predictor of All-Cause Mortality in Patients at High Risk of Cardiovascular Disease. ARTHRITIS& RHEUMATISM2008,58 (2):623-630
19. Wannamethee SG. Serum uric acid and risk of coronary heart disease. Curr Pharm Des, 2005,11:4125-4132.
20.别志欣.北京地区某体检人群高尿酸血症与代谢综合征的关系分析.北京：北京协和医学院,2008.
21. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc,2006,69:512-516.
22. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and themetabolic syndrome. Hepatology 2003:37:917-923.
23. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease:a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
24. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in non alcoholic fatty liver disease. Hepatology 2005;42:473-480.
25. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007:191:235-240.
26. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis:A systematic review. J Hepatol 2008:49:600-607.
27. Youming Li, Chengfu Xu, Chaohui Yu, et al. Association of serum uric acid level with non-alcoholic fatty liver disease:A cross-sectional study. Journal of Hepatology 50 (2009) 1029-1034
28. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol,2006,290:625-631.
29.罗荣高,杨兴仁,李东升.脂肪肝与血脂的关系探讨[J]临床军医杂志,2006,34(3)：30-31
30. Duffy W B, et al,Managment of asymptomatic hyperuricemia. JAMA, 1981.246(19):2215-2216
31. Dincer H E,Levinson D J, et al, Asymptomatic hyperuricemia:to treat or not to treat. Cleve Clin J Med,2002.69(8):594-597.
32. Lu ZS, Lu ZH, Lu H, et al. Association between hyperuricemia and hypertension in a Chinese population at a high risk of hypertension. [J]. Blood Press. 2009:18:268-72.
33.张红叶,李莹,陶寿淇,等.血清尿酸与四年后血压变化及高血压发病的关系.高血压杂志,2001,9(2)：160-163
34.赵兰江,赵冬,刘静,等.血清尿酸水平和甘油三酯关系的人群研究.中华内科杂志,2005,44(9)：664-667
35.冯续续,王蓓芸,崔亮,等.高血压病合并高尿酸血症与C反应蛋白的关系分析.中国临床医学,2005,13(1)：7-9.
36.吴敏,管晓峰,黄淑玉,等.2型糖尿病并高尿酸血症患者血浆hs-CRP水平的变化及意义.实用糖尿病杂志,2009,5(3)：54-55.
37. Duk-Hee Kang, Sung-Kwang Park, In-Kyu Lee, an. Richard J. Johnson et al. Uric Acid Induced C-Reactive Protein Expression:Implication on Cell Proliferation and Nitric Oxide Production of Human Vascular Cells. J Am Soc Nephrol 16:3553-3562, 2005.
38. Odeh MITumor necr osis fact or-alpha as a myocardial dep ressant substancel Int J cardial,1993,42 (3):231-2351
39. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure:a marker of chronic inflammation[J]. Eur Heart J,1998,19:1814-1822.
40.卢春燕,余敏,曾智,等.不同浓度尿酸对人脐静脉内皮细胞代谢的影响及胰岛素的协同损害作用.华西医学2004：19(3)：417-419.
41. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure results from 2 placebo-controlled studies [J]. Circulation,2002,105:2619-2624.
42. Zoccali C, Maio R, Mallamaci F, et al. Uric acid and endothelial dysfunction in essential hypertension [J]. J Am Soc Nephrol,2006,17:1466-1471.
43.肖立中,江志平,黄新,等.别嘌呤醇对冠心病患者内皮功能及心功能的影响[J].中国循环杂志,2003,18：16-18
44. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis[J]. Clin Chem,2009,55(2):229-238.
45. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease [J]. J Caediol,2009,53(3):317-333.
46. Chao LL, Xiu CQ, Zhi YP et al. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia[J]. Journal of Hypertension 2008,26:2326-2338.
47. Stavric B, Johnson WJ, Grice HC. Uric acid nephropathy:an experimental model [J].Proc Soc Exp Biol Med.1969; 130:512-516.
48.徐立,时乐.次黄嘌呤与氧嗪酸钾不同剂量配伍制备高尿酸血症大鼠模型.[J].中国药理学与毒理学杂志2008,22：306-310.
49. Johnson WJ, Stavric B, Chartrand A. Uricase inhibition in the rat by s-triazines: an animal model for hyperuricemia and hyperuricosuria. [J].Proc Soc Exp Biol Med. 1969; 131:8-12.
50. Ross R. The pathogenesis of atherosclerosis:a perspective for the 1990s [J]. Nature.1993,362:801-809
51. Maria Ines Schmidt, Robert L.Watson, Bruce B. Duncan, et al. Clustering of Dyslipidemia, Hyperuricemia, Diabetes, Diabetes, and Hyertension and Its Association With Fasting Insulin and Central and Overall Obesity in a General Population. Metabolism 1996,45(6):699-705
52.. Zalokar J, Lellouch J, Jean R, et al. Kuntz. epidemiology of serum uric acid and gout in franchmen. J Chron Dis,1974,27:59-75
53. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Pub Heal,2004,25:9-17
54..Nakanishi N, Tatara K, Nakamura K, et al. Risk factors for the incidence of hyperuriceamia:a 6-year longitudinal study of middle-aged Japanese men. Int J Epedemiol,1999,28:888-893
55. Zakynthinos E, Pappa N. Inf]lammatory biomarkers in coronary artery disease[J]. J Caediol,2009,53(3):317-333.
56. Gersch C, Palii SP, Kim KM, etal. Inactivation of nitric oxide by uric acid[J]. Nucleic Acids,2008,27:967-978.
57. Sautin YY, Johnson RJ. Uric acid:the oxidant-antioxidant paradox [J]. Nucleotides Nucleic Acids,2008,27:608-619.
58. Muraoka S, Miura T. Inhibition by uric acid of free radicals that damage biological molecules[J]. Pharmacol Toxicol,2003,93:284-289.
59. Cheng TH, LinJW, Chao HH, etal. Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts[J]. Int J Cardiol,2010,139(1):42-49.
60. DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque[J]. Neurology,1997,49:15-19.
61.徐勇,郑富荣,马红艳.氯沙坦对糖尿病大鼠腹主动脉超微结构的影响.泸州医学院院报,2004,27(1)：17-1
62.雷红,熊世熙,曹萍,等.实验性糖尿病大鼠主动脉的早期改变.数理医药杂志,2002,15(4)：299-300
63.刘雨清,张伟栋,段文卓.高糖、高脂血症时血管内皮细胞的变化解剖学进展.2001,7(2)：126-128
64. Shefer S. Nguyen LB, Salen G, et al. Differing effects of cholesterol and tauroeholate on steady state hepmic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities and mRNA levels in the rat[J]. Lipid Res,1992,33(8):1193-1200.
65. Mafia Luz Fernandez, Jeff S Volek. Guinea pigs:A suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation[J]. Nutr Metab,2006, 3:17.
66. M Rath, L Pauling. Immunological evidence for the accumulation of lipoprotein(a) in the atherosclerotic lesion ofthe hypoascorbemic guinea pig[J]. Proc Natl Acad Sci U S A.1990,87(23):9388-9390.
67. Mazzali M, Kanellis J,Han L,etal. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002,282:F991-F997.
68. Kosugi T, Nakayama T, Heinig M, etal. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice[J]. Am J Physiol Renal Physiol,2009,297:481-488.
[1]邵继红,莫宝庆,喻荣彬,等.南京市社区人群高尿酸血症与痛风的流行病学调查[J].疾病控制杂志,2003,7：305-308.
[2]吴炜戎,郭阶明,杨威,等.广州市社区痛风和高尿酸血症患病现状调查[J].中华全科医学,2008,6：728-729.
[3]Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease:a systematic review and meta-analysis. [J]. Arthritis Care Res (Hoboken).2010 Feb;62:170-180.
[4]Lu ZS, Lu ZH, Lu H, et al. Association between hyperuricemia and hypertension in a Chinese population at a high risk of hypertension. [J]. Blood Press.2009:18:268-72.
[5]Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes an inception cohort study[J]. Diabetes, 2009,58:1668-1671.
[6]Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke:a systematic review and meta-analysis. [J]. Arthritis Rheum.2009 Jul 15:61:885-92.
[7]Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease [J] Arthritis Rheum,2008,58:623-630.
[8]方厚华.高尿酸血症[M]//方厚华.医学实验模型动物.1.北京：军事医学科学出版社,2002.73-74.
[9]杨红莲,张冰,刘小青,等.雌性鹌鹑高尿酸血症模型研究[J]辽宁中医杂志,2009,36：6-8.
[10]潘志,段富津,王颖航,等.黄柏与苍术提取物对高尿酸血症小鼠血尿酸的影响[J].时珍国医国药.,2008,19：112-113.
[11]朱波,张亚海.三分三浸膏片对高尿酸血症小鼠血清尿酸含量的影响.[J].现代实用医学.2007,19：113-114
[12]Wu X, Muzny DM, Lee CC, et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. [J].J Mol Evol 34:78-84,1992.
[13]Stavric B, Johnson WJ, Grice HC. Uric acid nephropathy:an experimental model [J].Proc Soc Exp Biol Med.1969; 130:512-516.
[14]Chao LL, Xiu CQ, Zhi YP et al. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia[J]. Journal of Hypertension 2008,26:2326-2338.
[15]Laura G. Sa'nchez-Lozada, Virgilia Soto, Edilia Tapia, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. [J].Am J Physiol Renal Physiol 2008,295:F1134-F1141.
[16]高碧珍,李延平,李灿东,等.不同方药对高尿酸血症大鼠模型黄嘌呤氧化酶及肾功能的影响.：[J].中华中医药杂志。2008,23(2)：97-99
[17]杨维杰,徐厚谦,金华等.不同中医治法对高尿酸血症大鼠模型血清尿酸水平的影响比较[J].中医儿科杂志2007,3(2)：25-27
[18]Mazzali M, Hughes J, Kim YG, et al. Elevateduric acid increases blood pressure in the rat by a novel crystal-independent mechanism. [J]. Hypertension 2001,38: 1101-1106,.
[19]徐立,时乐.次黄嘌呤与氧嗪酸钾不同剂量配伍制备高尿酸血症大鼠模型.[J].中国药理学与毒理学杂志2008,22：306-310.
1. Daniel I. Feig, M. D., Ph.D., Duk-Hee Kang, M. D., and Richard J. Johnson, M. D. Uric Acid and Cardiovascular Risk, N Engl J Med 2008.359:1811-21
2.方圻,游凯,林其燧等,中国正常人血清尿酸调查及其与血脂的关系.中华内科杂志,1983,22：434-438.
3.杜蕙,陈顺乐,王元等.上海市黄浦区社区高尿酸血症与痛风流行病学调查.中华风湿病学杂志,1998,2：75-78.
4.方卫纲,黄晓明,王玉等,高尿酸血症在北京地区1997人中的患病情况及相关因素分析.中华医学杂志,2006,86：1764-1768.
5. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson, RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension.2002.40 (3):355-60
6. GERTLER MM, GARN SM, LEVINE SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med.1951 Jun;34(6):1421-31.
7. Robert D. ABBOTT, FREDERICK N. BRAND, WILLIAM B. KANNEL, WILLIAM P. CASTELLI. Gout and coronary heart disease:the Framingham study. J Clin Epidemiol,1988,41 (3):237-242.
8. Michael H. Alderman; Hillel Cohen; Shantha Madhavan; Salah Kivlighn. Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive Patients. Hypertension.1999:34:144-150.
9. Erdogan D, Gullu H, Caliskan M, Muderrisoglu H et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract.2005.59(11):1276-82.
10. Nobukazu Ishizaka, Yuko Ishizaka, Ei-Ichi Toda, Ryozo Nagai, Minoru Yamakado. Association Between Serum Uric Acid, Metabolic Syndrome, and Carotid Atherosclerosis in Japanese Individuals. Arterioscler Thromb Vasc Biol.2005; 25:1038-1044.
11. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow2up Study. Am J Epidemiol.1995,141:637-644
12. JIUNN-HOENF CHEN, SHAO-YUAN CHUANG, HSIN-JEN CHEN, et al. Serun uric acid level as an independent risk factor for all-cause cardiovascular, and ischemic stroke mortality:a Chinese cohort study. Arthritis and Rheumatism,2009,61(2):225-232
13.Adriana G. Ioachimescu, Danielle M. Brennan, Brian M. Hoar, Stanley L. Hazen, and Byron J. Hoogwerf. Serum Uric Acid Is an Independent Predictor of All-Cause Mortality in Patients at High Risk of Cardiovascular Disease, A Preventive Cardiology Information System (PreCIS) Database Cohort Study. ARTHRITIS& RHEUMATISM 2008.58(2):623-630.
14. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death:the Framingham Heart Study. Ann Intern Med 1999.131:7-13.
15. Wheeler JG, Juzwishin KD, Einksdottir。et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls:prospective study and meta-analysis. PLoS Medicine,2005.2(3):236-243..
16. FeigDI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003.42:247-252
17. Richard J. Johnson, Dan I. Feig, Jaime Herrera-Acosta and Duk-Hee Kang, Resurrection of Uric Acid as a Causal Risk Factor in Essential Hypertension, Hypertension 2005.45:18-20.
18. Kahn HA, MedalieJH, Neufeld HN, Riss E, Goldbourt U. The incidence of hypertension and associated factors:the Israel ischemic heart disease study. Am Heart J. 1972.84:171-182.
19. Selby JV, Friedman GD, Quesenberry CP, Jr.:Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol.1990.131:1017-1027.
20. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension.1991.17:969-976.
21.JossaF, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, Mancini M, Trevisan M. Serum uric acid and hypertension:the Olivetti heart study. J Hum Hypertens. 1994.8:677-681.
22.Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men. The Osaka Health Survey. J Hypertens.2001.19:1209-215.
23.Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension.2003.42:474-480.
24. Nakanishi N, Okamato M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type Ⅱ diabetes in Japanese male office workers. Eur J Epidemiol.2003.18:523-530.
25. Alper AB, Chen W, Yau L, Srinivasan S, Hamm LL, Berenson G. Childhood uric acid predicts adult blood pressure:The Bogalusa Heart Study. Hypertension. 2005.45:34-38.
26. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric aid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension.2005.45:28-33.
27. Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, Takashito S:Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004.27:835-841.
28. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007.49(2):298-303.
29. Perlstein TS, Gumieniak 0, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss. Uric acid and the development of hypertension:the normative aging study. Hypertension.2006.48(6):1031-6.
30. MellenPB, BleyerAJ, ErlingerTP, Evans GW, NietoFJ, Wagenknecht LE, Wofford. Serum uric acid predicts incident hypertension in a biethnic cohort:the atherosclerosis risk in communities study. Hypertension.2006.48(6):1037-42.
31.张红叶,李莹,陶寿淇,等.血清尿酸与四年后血压变化及高血压发病的关系.高血压杂志,2001,9(2)：160-163
32. Maria Ines Schmidt, Robert L.Watson, Bruce B. Duncan, et al. Clustering of Dyslipidemia, Hyperuricemia, Diabetes, Diabetes, and Hyertension and Its Association With Fasting Insulin and Central and Overall Obesity in a General Population.Metabolism 1996,45(6):699-705
33. Sugimori H, MiyakawaM, Yoshida K, et al. Health risk assessment for diabetes mellitus based on longitudinal analysis of MHTS database. J Med Syst.1998 Feb;22(1):27-32.
34. Tuomilehto J, Zimmet P, Wolf E, et al. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol.1988 Feb;127(2):321-36.
35. Zalokar J, LellouchJ, Jean R, et al. Kuntz. epidemiology of serum uric acid and gout in franchmen. J Chron Dis,1974,27:59-75
36. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Pub Heal, 2004,25:9-17
37.赵兰江,赵冬,刘静,等.血清尿酸水平和甘油三酯关系的人群研究.中华内科杂志,2005,44(9)：664-667
38. Nakanishi N, Tatara K, Nakamura K, et al. Risk factors for the incidence of hyperuriceamia:a 6-year longitudinal study of middle-aged Japanese men. Int J Epedemiol,1999,28:888-893
39. Kunitoshi Iseki, Yoshiharu Ikemiya, Shuichi Takishita et al, Significance of Hyperuricemia as a Risk Factor for Developing ESRD in a Screened Cohort, American Journal of Kidney Diseases,2004.44(4):642-650.
40. Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10:403-409
41. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44:642-650
42. Michel Chonchol, Michael G. Shlipak, Ronit Katz, Mark J. Sarnak, Anne B. Newman,David S. Siscovick, Bryan Kestenbaum, Jan Kirk Carney, and Linda F. Fried. Relationship of Uric Acid With Progression of Kidney Disease. Am J Kidney Dis 50:239-247
43. Rudolf P. Obermayr, Christian Temml, Georg Gutjahr, et al.Elevated Uric Acid Increases the Risk for Kidney Disease. J Am Soc Nephrol,2008.
44. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001.38:1101-6.
45. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction[J]. Kidney Int,2005,67:1739-1742.
46.张浩军,张冰,刘小青.小鼠高尿酸高脂血症复合模型初探.北京中医药大学学报,2001,24(6)：29-30
47.B. F. Becker, N. Reinholz, B. Leipert, P. Raschke, B. Permanetter and E. Gerlach, Role of Uric Acid as an Endogenous Radical Scavenger and Antioxidant,Chest 1991.100:176-181
48. Skinner KA, White CR, Patel R, Tan S, Barnes S, Kirk M, Darley-Usmar V, Parks DA. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem.1998.273 (38).-24491-7.
49. H. Ulrich Hink, Nalini Santanam, Tohru Fukai et al, Peroxidase Properties of Extracellular Superoxide Dismutase Role of Uric Acid in Modulating In Vivo Activity. Arteriosclerosis, Thrombosis, and Vascular Biology.2002.22:1402.
50. Ulf Landmesser and Helmut Drexler, Toward Understanding of Extracellular Superoxide Dismutase Regulation in Atherosclerosis:A Novel Role of Uric Acid? Arterioscler. Thromb. Vase. Biol.2002.22:1367-1368.
51.Boueiz, A.; Damarla, M.; Hassoun, P. M Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am J Physiol Lung Cell Mol Physiol,2008,294(5):830-840.
52. Chao HH, Liu JC, Lin JW, Chen CH, Wu CH, Cheng TH. Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin.2008.29(11):1301-12.
53. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes:NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol.2007 Aug.293(2):C584-96.
54. Hayden MR, Tyagi SC. Uric acid:A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus:The urate redox shuttle. Nutr Metab (Lond).2004.1(1):10.
55. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005 May.67(5):1739-42.
56. Duk-Hee Kang, Sung-Kwang Park, In-Kyu Lee and Richard J. Johnson. Uric Acid-Induced C-Reactive Protein Expression:Implication on Cell Proliferation and Nitric Oxide Production of Human Vascular Cells. J Am Soc Nephrol 2005.16:3553-3562.
57.Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER, Patel J.Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol.2008 Nov.295(5):C1183-90.
58.邹小秋,苏海,饶芳,李菊香,王光富,邓志华,尿酸对ECV304细胞的NO-NOS通路ADMA-DDAH系统影响。中国病理生理杂志。2006.22(01)：190-191,204.
59. Ruggiero C, Cherubini A, BleA, etal. Uric acid and inflammatory markers. Eur Heart J,2006,27(lo):1174-1181.
60. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, etal. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003.41:1287-93.
61. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (6957):516-521.
62. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991.266:8604-8.
63.Perlstein TS, Gumieniak 0, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND:Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004.66:1465-1470.
64. Santos CX, Anjos El, Augusto 0. Uric Acid Oxidation by Peroxynitrite:Multiple Reactions, Free Radical Formation, and Amplification of Lipid Oxidation. Archives of Biochemistry and Biophysics, Volume, Number, December 1999.372(2):285-294 (10).
65. Kang DH, Han L, Ouyang X, Kahn AM, Johnson RJ. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol.2005.25(5):425-33.
66. HOIEGGEN A, ALDERMAN M H, KJ ELDSENS E, et al. The impact of serum uric acid on cardiovascular outcomes in the L IFE study[J]. Kidney Int,2004,65:1041 1049
67. ATHYROS V G, ELISAFM, PAPA GEORGIOU A, et al. Effect of statins versus untreated dyslipi-demia on serum uric acid levels in patient s with coronary heart disease a subgroup analysis of the GREek. Atorvastatin and Coronary heart disease Evaluation. (GREACE) study [J]. Am J Kidney Dis,2004,43:589-599
68. Johnson WD, Kayser KL, Brenowitz JB, et al. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J,1991,121:20-24
69. Mercuro, G.; Vitale, C.; Cerquetani, E. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol,2004,94(7): 932-935.
70. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension:a randomized trial. JAMA. 2008 Aug 27.300(8):924-32.
71. Mehmet Kanbay, Adem Ozkara, Yusuf Selcoki, Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions, Int Urol Nephrol (2007) 39:1227-1233.
72. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric aid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension.2005.45:28-33.
73. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27(5):435-40.
74. Yui-Pong Siu, MRCP, Kay-Tai Leung, MRCP, Matthow Ka-Hang Tong, MRCP, Tze-Hci Kwan, FRCO. Use of Allopurinol in Slowing the Progression of Renal Disease Through its Ability to Lower Serum Uric Acid Level. Am J Kidney Dis 2006:47:51-59
75. Malaguarnera, M.; Vacante, M.; Russo, C. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother,2009.10(5):737-742.
2. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease:recent developments, and where do they leave us? Am J Med 2005; 118:816-26.
3. Feig DI, Kang DH, Johnson RJ. Uric Acid and Cardiovascular Risk. N Engl J Med 2008:359:1811-21.
4. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001.38:1101-6.
5.张浩军,张冰,刘小青.小鼠高尿酸高脂血症复合模型初探.[J]北京中医药大学学报200124(6)：29-30
6. Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults[J]. Int J Clin Pract, 2005,59:1276-1282.
7. Kanabrocki EL, Third JL, Ryan MD, et al. Circadian relationship of serum uric acid and nitric oxide[J]. JAMA,2000,283:2240-2241.
8. Kato M, Hisatome I, TomikuraY, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol.2005,96:1576-1578.
9. Khosla UM, Zharikov S, Finch JL,et al. Hyperuricemia induces endothelial dysfunction[J]. Kidney Int,2005,67:1739-1742.
10.方圻,游凯,林其燧等,中国正常人血清尿酸调查及其与血脂的关系.中华内科杂志,1983,22：434-438.
11.杜蕙,陈顺乐,王元等.上海市黄浦区社区高尿酸血症与痛风流行病学调查.中华风湿病学杂志,1998,2：75-78.
12.姜宝法,张源潮,徐晓菲,等.山东沿海地区痛风和高尿酸血症的流行病学调查[J].中国公共卫生,1999,15(3)：205-206
13.邵继红,莫宝庆,喻荣彬,等.南京市社区人群高尿酸血症与痛风的流行病学调查[J].疾病控制杂志,2003,7(4)：305-308
14.方卫纲,黄晓明,王玉等,高尿酸血症在北京地区1997人中的患病情况及相关因素分析.中华医学杂志,2006,86：1764-1768.
15. LeoNiskanen, David E. Laaksonen, Jaana Lindstr, et al. Serum Uric Acid as a Harbinger of Metabolic Outcome in Subjects With Impaired Glucose Tolerance. Diabetes Care, 2006,29, (3),709-711
16. Chin-Hsiao Tseng. Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney International,2005,68(3). 796-801.
17. Peter Hovind, Peter Rossing, Lise Tarnow, et al. Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes An Inception Cohort Study. Diabetes 2009,58(7):1668-1671.
18. Adriana G. Ioachimescu, Danielle M. Brennan, Brian M. Hoar, et al. Serum Uric Acid Is an Independent Predictor of All-Cause Mortality in Patients at High Risk of Cardiovascular Disease. ARTHRITIS& RHEUMATISM2008,58 (2):623-630
19. Wannamethee SG. Serum uric acid and risk of coronary heart disease. Curr Pharm Des, 2005,11:4125-4132.
20.别志欣.北京地区某体检人群高尿酸血症与代谢综合征的关系分析.北京：北京协和医学院,2008.
21. Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc,2006,69:512-516.
22. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and themetabolic syndrome. Hepatology 2003:37:917-923.
23. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease:a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
24. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in non alcoholic fatty liver disease. Hepatology 2005;42:473-480.
25. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007:191:235-240.
26. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis:A systematic review. J Hepatol 2008:49:600-607.
27. Youming Li, Chengfu Xu, Chaohui Yu, et al. Association of serum uric acid level with non-alcoholic fatty liver disease:A cross-sectional study. Journal of Hepatology 50 (2009) 1029-1034
28. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol,2006,290:625-631.
29.罗荣高,杨兴仁,李东升.脂肪肝与血脂的关系探讨[J]临床军医杂志,2006,34(3)：30-31
30. Duffy W B, et al,Managment of asymptomatic hyperuricemia. JAMA, 1981.246(19):2215-2216
31. Dincer H E,Levinson D J, et al, Asymptomatic hyperuricemia:to treat or not to treat. Cleve Clin J Med,2002.69(8):594-597.
32. Lu ZS, Lu ZH, Lu H, et al. Association between hyperuricemia and hypertension in a Chinese population at a high risk of hypertension. [J]. Blood Press. 2009:18:268-72.
33.张红叶,李莹,陶寿淇,等.血清尿酸与四年后血压变化及高血压发病的关系.高血压杂志,2001,9(2)：160-163
34.赵兰江,赵冬,刘静,等.血清尿酸水平和甘油三酯关系的人群研究.中华内科杂志,2005,44(9)：664-667
35.冯续续,王蓓芸,崔亮,等.高血压病合并高尿酸血症与C反应蛋白的关系分析.中国临床医学,2005,13(1)：7-9.
36.吴敏,管晓峰,黄淑玉,等.2型糖尿病并高尿酸血症患者血浆hs-CRP水平的变化及意义.实用糖尿病杂志,2009,5(3)：54-55.
37. Duk-Hee Kang, Sung-Kwang Park, In-Kyu Lee, an. Richard J. Johnson et al. Uric Acid Induced C-Reactive Protein Expression:Implication on Cell Proliferation and Nitric Oxide Production of Human Vascular Cells. J Am Soc Nephrol 16:3553-3562, 2005.
38. Odeh MITumor necr osis fact or-alpha as a myocardial dep ressant substancel Int J cardial,1993,42 (3):231-2351
39. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure:a marker of chronic inflammation[J]. Eur Heart J,1998,19:1814-1822.
40.卢春燕,余敏,曾智,等.不同浓度尿酸对人脐静脉内皮细胞代谢的影响及胰岛素的协同损害作用.华西医学2004：19(3)：417-419.
41. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure results from 2 placebo-controlled studies [J]. Circulation,2002,105:2619-2624.
42. Zoccali C, Maio R, Mallamaci F, et al. Uric acid and endothelial dysfunction in essential hypertension [J]. J Am Soc Nephrol,2006,17:1466-1471.
43.肖立中,江志平,黄新,等.别嘌呤醇对冠心病患者内皮功能及心功能的影响[J].中国循环杂志,2003,18：16-18
44. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis[J]. Clin Chem,2009,55(2):229-238.
45. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease [J]. J Caediol,2009,53(3):317-333.
46. Chao LL, Xiu CQ, Zhi YP et al. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia[J]. Journal of Hypertension 2008,26:2326-2338.
47. Stavric B, Johnson WJ, Grice HC. Uric acid nephropathy:an experimental model [J].Proc Soc Exp Biol Med.1969; 130:512-516.
48.徐立,时乐.次黄嘌呤与氧嗪酸钾不同剂量配伍制备高尿酸血症大鼠模型.[J].中国药理学与毒理学杂志2008,22：306-310.
49. Johnson WJ, Stavric B, Chartrand A. Uricase inhibition in the rat by s-triazines: an animal model for hyperuricemia and hyperuricosuria. [J].Proc Soc Exp Biol Med. 1969; 131:8-12.
50. Ross R. The pathogenesis of atherosclerosis:a perspective for the 1990s [J]. Nature.1993,362:801-809
51. Maria Ines Schmidt, Robert L.Watson, Bruce B. Duncan, et al. Clustering of Dyslipidemia, Hyperuricemia, Diabetes, Diabetes, and Hyertension and Its Association With Fasting Insulin and Central and Overall Obesity in a General Population. Metabolism 1996,45(6):699-705
52.. Zalokar J, Lellouch J, Jean R, et al. Kuntz. epidemiology of serum uric acid and gout in franchmen. J Chron Dis,1974,27:59-75
53. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Pub Heal,2004,25:9-17
54..Nakanishi N, Tatara K, Nakamura K, et al. Risk factors for the incidence of hyperuriceamia:a 6-year longitudinal study of middle-aged Japanese men. Int J Epedemiol,1999,28:888-893
55. Zakynthinos E, Pappa N. Inf]lammatory biomarkers in coronary artery disease[J]. J Caediol,2009,53(3):317-333.
56. Gersch C, Palii SP, Kim KM, etal. Inactivation of nitric oxide by uric acid[J]. Nucleic Acids,2008,27:967-978.
57. Sautin YY, Johnson RJ. Uric acid:the oxidant-antioxidant paradox [J]. Nucleotides Nucleic Acids,2008,27:608-619.
58. Muraoka S, Miura T. Inhibition by uric acid of free radicals that damage biological molecules[J]. Pharmacol Toxicol,2003,93:284-289.
59. Cheng TH, LinJW, Chao HH, etal. Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts[J]. Int J Cardiol,2010,139(1):42-49.
60. DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque[J]. Neurology,1997,49:15-19.
61.徐勇,郑富荣,马红艳.氯沙坦对糖尿病大鼠腹主动脉超微结构的影响.泸州医学院院报,2004,27(1)：17-1
62.雷红,熊世熙,曹萍,等.实验性糖尿病大鼠主动脉的早期改变.数理医药杂志,2002,15(4)：299-300
63.刘雨清,张伟栋,段文卓.高糖、高脂血症时血管内皮细胞的变化解剖学进展.2001,7(2)：126-128
64. Shefer S. Nguyen LB, Salen G, et al. Differing effects of cholesterol and tauroeholate on steady state hepmic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities and mRNA levels in the rat[J]. Lipid Res,1992,33(8):1193-1200.
65. Mafia Luz Fernandez, Jeff S Volek. Guinea pigs:A suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation[J]. Nutr Metab,2006, 3:17.
66. M Rath, L Pauling. Immunological evidence for the accumulation of lipoprotein(a) in the atherosclerotic lesion ofthe hypoascorbemic guinea pig[J]. Proc Natl Acad Sci U S A.1990,87(23):9388-9390.
67. Mazzali M, Kanellis J,Han L,etal. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002,282:F991-F997.
68. Kosugi T, Nakayama T, Heinig M, etal. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice[J]. Am J Physiol Renal Physiol,2009,297:481-488.
[1]邵继红,莫宝庆,喻荣彬,等.南京市社区人群高尿酸血症与痛风的流行病学调查[J].疾病控制杂志,2003,7：305-308.
[2]吴炜戎,郭阶明,杨威,等.广州市社区痛风和高尿酸血症患病现状调查[J].中华全科医学,2008,6：728-729.
[3]Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease:a systematic review and meta-analysis. [J]. Arthritis Care Res (Hoboken).2010 Feb;62:170-180.
[4]Lu ZS, Lu ZH, Lu H, et al. Association between hyperuricemia and hypertension in a Chinese population at a high risk of hypertension. [J]. Blood Press.2009:18:268-72.
[5]Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes an inception cohort study[J]. Diabetes, 2009,58:1668-1671.
[6]Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke:a systematic review and meta-analysis. [J]. Arthritis Rheum.2009 Jul 15:61:885-92.
[7]Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease [J] Arthritis Rheum,2008,58:623-630.
[8]方厚华.高尿酸血症[M]//方厚华.医学实验模型动物.1.北京：军事医学科学出版社,2002.73-74.
[9]杨红莲,张冰,刘小青,等.雌性鹌鹑高尿酸血症模型研究[J]辽宁中医杂志,2009,36：6-8.
[10]潘志,段富津,王颖航,等.黄柏与苍术提取物对高尿酸血症小鼠血尿酸的影响[J].时珍国医国药.,2008,19：112-113.
[11]朱波,张亚海.三分三浸膏片对高尿酸血症小鼠血清尿酸含量的影响.[J].现代实用医学.2007,19：113-114
[12]Wu X, Muzny DM, Lee CC, et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. [J].J Mol Evol 34:78-84,1992.
[13]Stavric B, Johnson WJ, Grice HC. Uric acid nephropathy:an experimental model [J].Proc Soc Exp Biol Med.1969; 130:512-516.
[14]Chao LL, Xiu CQ, Zhi YP et al. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia[J]. Journal of Hypertension 2008,26:2326-2338.
[15]Laura G. Sa'nchez-Lozada, Virgilia Soto, Edilia Tapia, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. [J].Am J Physiol Renal Physiol 2008,295:F1134-F1141.
[16]高碧珍,李延平,李灿东,等.不同方药对高尿酸血症大鼠模型黄嘌呤氧化酶及肾功能的影响.：[J].中华中医药杂志。2008,23(2)：97-99
[17]杨维杰,徐厚谦,金华等.不同中医治法对高尿酸血症大鼠模型血清尿酸水平的影响比较[J].中医儿科杂志2007,3(2)：25-27
[18]Mazzali M, Hughes J, Kim YG, et al. Elevateduric acid increases blood pressure in the rat by a novel crystal-independent mechanism. [J]. Hypertension 2001,38: 1101-1106,.
[19]徐立,时乐.次黄嘌呤与氧嗪酸钾不同剂量配伍制备高尿酸血症大鼠模型.[J].中国药理学与毒理学杂志2008,22：306-310.
1. Daniel I. Feig, M. D., Ph.D., Duk-Hee Kang, M. D., and Richard J. Johnson, M. D. Uric Acid and Cardiovascular Risk, N Engl J Med 2008.359:1811-21
2.方圻,游凯,林其燧等,中国正常人血清尿酸调查及其与血脂的关系.中华内科杂志,1983,22：434-438.
3.杜蕙,陈顺乐,王元等.上海市黄浦区社区高尿酸血症与痛风流行病学调查.中华风湿病学杂志,1998,2：75-78.
4.方卫纲,黄晓明,王玉等,高尿酸血症在北京地区1997人中的患病情况及相关因素分析.中华医学杂志,2006,86：1764-1768.
5. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson, RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension.2002.40 (3):355-60
6. GERTLER MM, GARN SM, LEVINE SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med.1951 Jun;34(6):1421-31.
7. Robert D. ABBOTT, FREDERICK N. BRAND, WILLIAM B. KANNEL, WILLIAM P. CASTELLI. Gout and coronary heart disease:the Framingham study. J Clin Epidemiol,1988,41 (3):237-242.
8. Michael H. Alderman; Hillel Cohen; Shantha Madhavan; Salah Kivlighn. Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive Patients. Hypertension.1999:34:144-150.
9. Erdogan D, Gullu H, Caliskan M, Muderrisoglu H et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract.2005.59(11):1276-82.
10. Nobukazu Ishizaka, Yuko Ishizaka, Ei-Ichi Toda, Ryozo Nagai, Minoru Yamakado. Association Between Serum Uric Acid, Metabolic Syndrome, and Carotid Atherosclerosis in Japanese Individuals. Arterioscler Thromb Vasc Biol.2005; 25:1038-1044.
11. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow2up Study. Am J Epidemiol.1995,141:637-644
12. JIUNN-HOENF CHEN, SHAO-YUAN CHUANG, HSIN-JEN CHEN, et al. Serun uric acid level as an independent risk factor for all-cause cardiovascular, and ischemic stroke mortality:a Chinese cohort study. Arthritis and Rheumatism,2009,61(2):225-232
13.Adriana G. Ioachimescu, Danielle M. Brennan, Brian M. Hoar, Stanley L. Hazen, and Byron J. Hoogwerf. Serum Uric Acid Is an Independent Predictor of All-Cause Mortality in Patients at High Risk of Cardiovascular Disease, A Preventive Cardiology Information System (PreCIS) Database Cohort Study. ARTHRITIS& RHEUMATISM 2008.58(2):623-630.
14. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death:the Framingham Heart Study. Ann Intern Med 1999.131:7-13.
15. Wheeler JG, Juzwishin KD, Einksdottir。et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls:prospective study and meta-analysis. PLoS Medicine,2005.2(3):236-243..
16. FeigDI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003.42:247-252
17. Richard J. Johnson, Dan I. Feig, Jaime Herrera-Acosta and Duk-Hee Kang, Resurrection of Uric Acid as a Causal Risk Factor in Essential Hypertension, Hypertension 2005.45:18-20.
18. Kahn HA, MedalieJH, Neufeld HN, Riss E, Goldbourt U. The incidence of hypertension and associated factors:the Israel ischemic heart disease study. Am Heart J. 1972.84:171-182.
19. Selby JV, Friedman GD, Quesenberry CP, Jr.:Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol.1990.131:1017-1027.
20. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension.1991.17:969-976.
21.JossaF, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, Mancini M, Trevisan M. Serum uric acid and hypertension:the Olivetti heart study. J Hum Hypertens. 1994.8:677-681.
22.Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men. The Osaka Health Survey. J Hypertens.2001.19:1209-215.
23.Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension.2003.42:474-480.
24. Nakanishi N, Okamato M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type Ⅱ diabetes in Japanese male office workers. Eur J Epidemiol.2003.18:523-530.
25. Alper AB, Chen W, Yau L, Srinivasan S, Hamm LL, Berenson G. Childhood uric acid predicts adult blood pressure:The Bogalusa Heart Study. Hypertension. 2005.45:34-38.
26. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric aid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension.2005.45:28-33.
27. Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, Takashito S:Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004.27:835-841.
28. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007.49(2):298-303.
29. Perlstein TS, Gumieniak 0, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss. Uric acid and the development of hypertension:the normative aging study. Hypertension.2006.48(6):1031-6.
30. MellenPB, BleyerAJ, ErlingerTP, Evans GW, NietoFJ, Wagenknecht LE, Wofford. Serum uric acid predicts incident hypertension in a biethnic cohort:the atherosclerosis risk in communities study. Hypertension.2006.48(6):1037-42.
31.张红叶,李莹,陶寿淇,等.血清尿酸与四年后血压变化及高血压发病的关系.高血压杂志,2001,9(2)：160-163
32. Maria Ines Schmidt, Robert L.Watson, Bruce B. Duncan, et al. Clustering of Dyslipidemia, Hyperuricemia, Diabetes, Diabetes, and Hyertension and Its Association With Fasting Insulin and Central and Overall Obesity in a General Population.Metabolism 1996,45(6):699-705
33. Sugimori H, MiyakawaM, Yoshida K, et al. Health risk assessment for diabetes mellitus based on longitudinal analysis of MHTS database. J Med Syst.1998 Feb;22(1):27-32.
34. Tuomilehto J, Zimmet P, Wolf E, et al. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol.1988 Feb;127(2):321-36.
35. Zalokar J, LellouchJ, Jean R, et al. Kuntz. epidemiology of serum uric acid and gout in franchmen. J Chron Dis,1974,27:59-75
36. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Pub Heal, 2004,25:9-17
37.赵兰江,赵冬,刘静,等.血清尿酸水平和甘油三酯关系的人群研究.中华内科杂志,2005,44(9)：664-667
38. Nakanishi N, Tatara K, Nakamura K, et al. Risk factors for the incidence of hyperuriceamia:a 6-year longitudinal study of middle-aged Japanese men. Int J Epedemiol,1999,28:888-893
39. Kunitoshi Iseki, Yoshiharu Ikemiya, Shuichi Takishita et al, Significance of Hyperuricemia as a Risk Factor for Developing ESRD in a Screened Cohort, American Journal of Kidney Diseases,2004.44(4):642-650.
40. Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10:403-409
41. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44:642-650
42. Michel Chonchol, Michael G. Shlipak, Ronit Katz, Mark J. Sarnak, Anne B. Newman,David S. Siscovick, Bryan Kestenbaum, Jan Kirk Carney, and Linda F. Fried. Relationship of Uric Acid With Progression of Kidney Disease. Am J Kidney Dis 50:239-247
43. Rudolf P. Obermayr, Christian Temml, Georg Gutjahr, et al.Elevated Uric Acid Increases the Risk for Kidney Disease. J Am Soc Nephrol,2008.
44. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001.38:1101-6.
45. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction[J]. Kidney Int,2005,67:1739-1742.
46.张浩军,张冰,刘小青.小鼠高尿酸高脂血症复合模型初探.北京中医药大学学报,2001,24(6)：29-30
47.B. F. Becker, N. Reinholz, B. Leipert, P. Raschke, B. Permanetter and E. Gerlach, Role of Uric Acid as an Endogenous Radical Scavenger and Antioxidant,Chest 1991.100:176-181
48. Skinner KA, White CR, Patel R, Tan S, Barnes S, Kirk M, Darley-Usmar V, Parks DA. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem.1998.273 (38).-24491-7.
49. H. Ulrich Hink, Nalini Santanam, Tohru Fukai et al, Peroxidase Properties of Extracellular Superoxide Dismutase Role of Uric Acid in Modulating In Vivo Activity. Arteriosclerosis, Thrombosis, and Vascular Biology.2002.22:1402.
50. Ulf Landmesser and Helmut Drexler, Toward Understanding of Extracellular Superoxide Dismutase Regulation in Atherosclerosis:A Novel Role of Uric Acid? Arterioscler. Thromb. Vase. Biol.2002.22:1367-1368.
51.Boueiz, A.; Damarla, M.; Hassoun, P. M Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am J Physiol Lung Cell Mol Physiol,2008,294(5):830-840.
52. Chao HH, Liu JC, Lin JW, Chen CH, Wu CH, Cheng TH. Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin.2008.29(11):1301-12.
53. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes:NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol.2007 Aug.293(2):C584-96.
54. Hayden MR, Tyagi SC. Uric acid:A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus:The urate redox shuttle. Nutr Metab (Lond).2004.1(1):10.
55. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005 May.67(5):1739-42.
56. Duk-Hee Kang, Sung-Kwang Park, In-Kyu Lee and Richard J. Johnson. Uric Acid-Induced C-Reactive Protein Expression:Implication on Cell Proliferation and Nitric Oxide Production of Human Vascular Cells. J Am Soc Nephrol 2005.16:3553-3562.
57.Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER, Patel J.Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol.2008 Nov.295(5):C1183-90.
58.邹小秋,苏海,饶芳,李菊香,王光富,邓志华,尿酸对ECV304细胞的NO-NOS通路ADMA-DDAH系统影响。中国病理生理杂志。2006.22(01)：190-191,204.
59. Ruggiero C, Cherubini A, BleA, etal. Uric acid and inflammatory markers. Eur Heart J,2006,27(lo):1174-1181.
60. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, etal. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003.41:1287-93.
61. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (6957):516-521.
62. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991.266:8604-8.
63.Perlstein TS, Gumieniak 0, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND:Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004.66:1465-1470.
64. Santos CX, Anjos El, Augusto 0. Uric Acid Oxidation by Peroxynitrite:Multiple Reactions, Free Radical Formation, and Amplification of Lipid Oxidation. Archives of Biochemistry and Biophysics, Volume, Number, December 1999.372(2):285-294 (10).
65. Kang DH, Han L, Ouyang X, Kahn AM, Johnson RJ. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol.2005.25(5):425-33.
66. HOIEGGEN A, ALDERMAN M H, KJ ELDSENS E, et al. The impact of serum uric acid on cardiovascular outcomes in the L IFE study[J]. Kidney Int,2004,65:1041 1049
67. ATHYROS V G, ELISAFM, PAPA GEORGIOU A, et al. Effect of statins versus untreated dyslipi-demia on serum uric acid levels in patient s with coronary heart disease a subgroup analysis of the GREek. Atorvastatin and Coronary heart disease Evaluation. (GREACE) study [J]. Am J Kidney Dis,2004,43:589-599
68. Johnson WD, Kayser KL, Brenowitz JB, et al. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J,1991,121:20-24
69. Mercuro, G.; Vitale, C.; Cerquetani, E. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol,2004,94(7): 932-935.
70. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension:a randomized trial. JAMA. 2008 Aug 27.300(8):924-32.
71. Mehmet Kanbay, Adem Ozkara, Yusuf Selcoki, Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions, Int Urol Nephrol (2007) 39:1227-1233.
72. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric aid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension.2005.45:28-33.
73. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27(5):435-40.
74. Yui-Pong Siu, MRCP, Kay-Tai Leung, MRCP, Matthow Ka-Hang Tong, MRCP, Tze-Hci Kwan, FRCO. Use of Allopurinol in Slowing the Progression of Renal Disease Through its Ability to Lower Serum Uric Acid Level. Am J Kidney Dis 2006:47:51-59
75. Malaguarnera, M.; Vacante, M.; Russo, C. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother,2009.10(5):737-742.